Business
IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Jan. 12, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 43rd Annual J.P. Morgan Healthcare Conference and provided 2025 corporate guidance and program updates.\n\n \n \n \n \n \n \n\n \n43rd Annual J.P. Morgan Healthcare ConferenceMonday, January 13th, 2025, at 5:15 PM PT (8:15 PM ET)\nPresentation by Yujiro S. Hata, Chief Executive Officer, IDEAYA Biosciences, followed by analyst-hosted Q&A with Anupam Rama, Managing Director, US SMID Biotechnology Equity Research, J.P. Morgan2025 Corporate Guidance to be Presented at the 43rd Annual J.P. Morgan Healthcare Conference: \nCorporate financial guidance$1.2 billion of cash, cash equivalents and marketable securities as of September 30, 2024, is anticipated to fund operations into at least 2028Darovasertib, a potential first-in-class Phase 2/3 PKC inhibitor program targeting Metastatic Uveal Melanoma (MUM) and Uveal Melanoma (UM)Median progression free survival readout for potential Phase 2/3 registration-enabling trial of the darovasertib and crizotinib combination in first-line (1L) patients with HLA-A2-negative MUM targeted by year-end 2025, pending enrollment status and data maturity. Enrollment has exceeded over 200 patients as of January 6, 2025Phase 2 1L MUM median overall survival readout for the darovasertib and crizotinib combination in approximately 38 1L MUM patients targeted in 2025Targeting Phase 2 neoadjuvant UM clinical data update for darovasertib in over 75 patients and a regulatory update in 2025Initiation of the Phase 3 registration-enabling trial for darovasertib in neoadjuvant UM is planned for the first half of 2025IDE397, a potential first-in-class Phase 2 MAT2A Inhibitor program targeting MTAP-deletion solid tumorsClinical program update(s) for Phase 1/2 study of IDE397 in combination with Trodelvy® in MTAP-deletion urothelial cancer (UC) in 2025Target to enable wholly owned IDE397 + IDE892 (IDEAYA PRMT5) clinical combination in the second half of 2025 to target MTAP-deletion non-small cell lung cancer (NSCLC)IDE849 (SHR-4849), a potential first-in-class Phase 1 DLL3 TOP1i ADC targeting Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NETs)Clinical program update(s) ta...